Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years
AUTOR(ES)
Farlow, Martin R
FONTE
BioMed Central
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=548267Documentos Relacionados
- Open-Label, Dose Escalation Study of the Safety and Pharmacokinetic Profile of Tefibazumab in Healthy Volunteers
- Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease
- Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial
- Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial
- Open‐label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study